News & Updates

Show Multimedia Only
Nivolumab plus cabozantinib superior to sunitinib in renal cell carcinoma

Nivolumab plus cabozantinib superior to sunitinib in renal cell carcinoma

03 Mar 2023 byStephen Padilla

First-line treatment of advanced renal cell carcinoma (aRCC) with nivolumab plus cabozantinib (N+C) results in sustained survival and response benefits at 3 years minimum follow-up, which is consistent with previous follow-ups, according to a study presented at the 2023 ASCO GU Cancers Symposium.

03 Mar 2023
Infertility implicated in obesity-related reproductive cancers

Infertility implicated in obesity-related reproductive cancers

03 Mar 2023

Women with a history of infertility are more likely to develop reproductive cancers that are related to obesity, as reported in a study.

03 Mar 2023